2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our latest newsletter for a look back at the highlights as well as a look ahead at what’s on the way for...
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid tumors SAN DIEGO, Calif., and Singapore – December 21, 2023 – ImmunoScape, a biotechnology...
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on novel cell therapies as well as bispecific immune cell...
Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric Antigen Receptor was reported, CAR-T cell therapies have seen significant breakthroughs managing liquid...
The ImmunoScape team is heading to the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco in a few weeks. Our CEO Choon-Peng (Choon) Ng, our Vice President, Discovery Dan MacLeod, and our Senior Director, Business Development Christopher Alfonso will be in...
